Objective: To observe the expression of estrogen receptor and the activity of NOS in the arteries of female rats receiving estrogen replacement therapy. Methods: Seventy-two female rats were randomly divided into four groups: group A: sham-ovariectomy; group B: ovariectomy; group C: ovariectomy with estrogen replacement therapy (benzoate estradiol, 5 μg i.m. once in 2 days); group D: ovariectomy with estrogen and progesterone replacement therapy (benzoate estradiol, 5 μg i.m. once in 2 days and progesterone, 1 mg i.m. once in 2 days). The rats were killed after 2 months. The receptor-binding assay was adopted to measure the estrogen receptors in the arteries of the rats, and the activity of NOS in the arteries was assessed by the hemoglobin reductase method. Results: The ER number and NOS activity in the arteries of the ovariectomized group are less than those in sham-ovariectomy group (p < 0.05). The ER number and NOS activity in the arteries of groups C and D are larger and higher than those in the ovariectomized group (p < 0.05). No significant differences in the ER number and NOS activity were observed between groups C and D. Conclusion: The ER number and NOS activity in the rat artery significantly decrease after ovariectomy, while hormone replacement therapy can significantly increase the artery NOS activity and retain the ER number in the artery of the ovariectomized rats to normal level. The result may contribute to explaining the beneficial effect of estrogen in the prevention of coronary artery diseases in postmenopausal women.

Keywords:
Estrogen receptor, Estrogen replacement therapy, Atherosclerosis, Nitric oxide
1.
Stampfer MJ, Colditz GA, Willtt WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med 1991;325:756–762.
2.
Gevers Leuven JA: Sex steroids and lipoprotein metabolism. Pharmacol Ther 1994;64:99–126.
3.
Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1995;273:199–208.
4.
Barrett-Conner E, Bush TL: Estrogen and coronary heart disease. JAMA 1991;10:1102–1109.
5.
Karas RH, Patterson BL, Mendelsohn ME: Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994;89:1943–1950.
6.
Kim-Schulze S, Mcgowan KA, Hubchak SC, Cid MC, Martin MB, Kleinman HK, Greene GL, Schnaper HW: Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation 1996;94:1402–1407.
7.
Latin-Hermoso RL, Rosenfeld CR, Yuhanna IS, German Z, Chen Z, Shaul PW: Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. Am J Physiol 1997;273:L119–L126.
8.
Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM: Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994;89:1501–1510.
9.
Korach KS: Estrogen action in the mouse uterus: Characterization of the cytosolic and nuclear receptor system. Endocrinology 1979;104:1324–1332.
10.
Scatchard G: The attraction of proteins for small molecules and ions. Am NY Acad Sci 1949;51:660–672.
11.
Bush TL, Barrett-Conner E, Cowan LD, Cirqui MH, Wallaca RB, Scucindran CM, Tyroler HA: Cardiovascular mortality and noncontraceptive use of estrogen in women. Results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102–1109.
12.
Wagner JD, Clarkson TB, Clair RW: Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 1991;88:1995–2002.
13.
Widerpass E, Adami HO, Baron JA: Risk of endometrial cancer following estrogen replacement with and without progestin. J Natl Cancer Inst 1999;91:1131–1137.
14.
Fahraeus L, Sydsijo A, Wallentin L: Lipoprotein changes during treatment of pelvic endometriosis with medroxy progesterone acetate. Fertil Steril 1986;45:503–506.
15.
Chen FP, Lee N, Soong YK: Changes in the lipoprotein profile in postmenopausal women receiving hormone replacement therapy: Effects of natural and synthetic progesterone. J Reprod Med 1998;43:568–574.
16.
Caulin-Glaser T, Garcia-Cardena G, Sarrel P, Sessa WC, Bender JR: 17β-Estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res 1997;81:885–892.
17.
Rubanyl GM, Freay AD, Kauser K, Sukovich D, Burton G, Lubahn DB, Couse JF, Curtis SW, Korach KS: Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. J Clin Invest 1997;99:2429–2437.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.